Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SELP | P16109 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1776704 | 0.84 | KMT2A (0.50) | L3MBTL1KMT2AMEN1ALDH1A1SELP | |
| SCHEMBL10755879 | 0.84 | KMT2A (0.50) | L3MBTL1KMT2AMEN1ALDH1A1SELP | |
| SCHEMBL1776705 | 0.84 | KMT2A (0.50) | L3MBTL1KMT2AMEN1ALDH1A1SELP | |
| SCHEMBL19674474 | 0.84 | KMT2A (0.50) | L3MBTL1KMT2AMEN1ALDH1A1SELP | |
| SCHEMBL10755871 | 0.84 | KMT2A (0.50) | L3MBTL1KMT2AMEN1ALDH1A1SELP | |
| SCHEMBL19731863 | 0.75 | L3MBTL1 (0.44) | L3MBTL1KMT2AMEN1ALDH1A1 | |
| SCHEMBL10907214 | 0.72 | L3MBTL1 (0.49) | L3MBTL1KMT2AMEN1ALDH1A1SELP | |
| SCHEMBL9856267 | 0.71 | KMT2A (0.53) | L3MBTL1KMT2AMEN1ALDH1A1BCHE | |
| SCHEMBL22002346 | 0.70 | L3MBTL1 (0.41) | L3MBTL1KMT2AMEN1ALDH1A1SELP | |
| SCHEMBL23742935 | 0.69 | L3MBTL1 (0.49) | L3MBTL1KMT2AMEN1ALDH1A1SELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039367-A1 | Medicinal Composition Containing Diabeted Remedy | SANKYO COMPANY, LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039367-A1 | Medicinal Composition Containing Diabeted Remedy | DPP4, IAPP, AMY2A | L3MBTL1 3736/4885KMT2A 2488/4885MEN1 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.